{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:16:24Z","timestamp":1793106984218,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.yrtph.2026.106051","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:06:27Z","timestamp":1769792787000},"page":"106051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7106-830X","authenticated-orcid":false,"given":"Robert A.","family":"Jolly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Trejo-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel P.","family":"Bercu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Powley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael E.","family":"Tennant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Ponting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Sobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Czich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana","family":"Kobets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheroy","family":"Minocherhomji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6726-7227","authenticated-orcid":false,"given":"Raechel","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106051_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.105835","article-title":"HESI GTTC ring trial: concordance between ames and rodent carcinogenicity outcomes for N-Nitrosamines (NAs) with rat and Hamster Metabolic conditions","volume":"161","author":"Bercu","year":"2025","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106051_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105704","article-title":"N-Nitrosamine drug substance related impurities (NDSRIs) - a proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da","volume":"154","author":"Bercu","year":"2024","journal-title":"Regul. Toxicol. Pharmacol. : RTP (Regul. Toxicol. Pharmacol.)"},{"key":"10.1016\/j.yrtph.2026.106051_bib3","series-title":"Acceptable Intakes (AIs) for 11 Small Molecule N-nitrosamines (NAs)","author":"Bercu","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106051_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrgentox.2023.503685","article-title":"Comparison of the transgenic rodent mutation assay, error corrected next generation duplex sequencing, and the alkaline comet assay to detect dose-related mutations following exposure to N-nitrosodiethylamine","volume":"891","author":"Bercu","year":"2023","journal-title":"Mutat. Res., Genet. Toxicol. Environ. Mutagen."},{"issue":"6\u20137","key":"10.1016\/j.yrtph.2026.106051_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/em.22618","article-title":"Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential","volume":"65","author":"Cheung","year":"2024","journal-title":"Environ. Mol. Mutagen."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106051_bib6","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of N-Nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.yrtph.2026.106051_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.toxrep.2024.01.012","article-title":"Metabolic activation of short-chain alkyl N-nitrosamines using Aroclor 1254 or phenobarbital\/beta-naphthoflavone-induced rat or hamster S9\u2014A comparative analysis","volume":"12","author":"Dieckhoff","year":"2024","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.yrtph.2026.106051_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105288","article-title":"Setting limits for N-nitrosamines in drugs: a defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities","volume":"136","author":"Dos Santos","year":"2022","journal-title":"Regul. Toxicol. Pharmacol.: RTP (Regul. Toxicol. Pharmacol.)"},{"key":"10.1016\/j.yrtph.2026.106051_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrgentox.2025.503855","article-title":"A comparative analysis of select P450 enzymes in uninduced and PB\/BNF-induced hamster and rat liver S9","volume":"902","author":"Evans","year":"2025","journal-title":"Mutat. Res., Genet. Toxicol. Environ. Mutagen."},{"key":"10.1016\/j.yrtph.2026.106051_bib11","series-title":"CDER Nitrosamine Impurity Acceptable Intake Limits","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106051_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105245","article-title":"Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity","volume":"134","author":"Glowienke","year":"2022","journal-title":"Regul. Toxicol. Pharmacol.: RTP (Regul. Toxicol. Pharmacol.)"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106051_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/em.21727","article-title":"Quantitative approaches for assessing dose-response relationships in genetic toxicology studies","volume":"54","author":"Gollapudi","year":"2013","journal-title":"Environ. Mol. Mutagen."},{"issue":"9","key":"10.1016\/j.yrtph.2026.106051_bib14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/em.22408","article-title":"Genotoxicity as a toxicologically relevant endpoint to inform risk assessment: a case study with ethylene oxide","volume":"61","author":"Gollapudi","year":"2020","journal-title":"Environ. Mol. Mutagen."},{"issue":"23 Pt 2","key":"10.1016\/j.yrtph.2026.106051_bib15","first-page":"6470","article-title":"Chronic nitrosamine ingestion in 1040 rodents: the effect of the choice of nitrosamine, the species studied, and the age of starting exposure","volume":"51","author":"Gray","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.yrtph.2026.106051_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105709","article-title":"Optimizing the detection of N-nitrosamine mutagenicity in the Ames test","volume":"153","author":"Heflich","year":"2024","journal-title":"Regul. Toxicol. Pharmacol.: RTP (Regul. Toxicol. Pharmacol.)"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106051_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/em.22338","article-title":"Mutation as a toxicological endpoint for regulatory decision-making","volume":"61","author":"Heflich","year":"2020","journal-title":"Environ. Mol. Mutagen."},{"issue":"7","key":"10.1016\/j.yrtph.2026.106051_bib19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/em.20651","article-title":"Can carcinogenic potency be predicted from in vivo genotoxicity data?: a meta-analysis of historical data","volume":"52","author":"Hern\u00e1ndez","year":"2011","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.yrtph.2026.106051_bib20","series-title":"HESI GTTC Nitrosamines Research Program","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106051_bib21","series-title":"ICH M7(R2) Guideline: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk\u2014Questions and Answers","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106051_bib22","series-title":"Application of the Principles of the ICH M7 Guideline to Calculation of Compound-specific Acceptable Intakes Addendum to M7(R2)","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106051_bib23","series-title":"Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenicrisk M7(R2)","year":"2023"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106051_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/em.22446","article-title":"Permitted daily exposure limits for noteworthy N-nitrosamines","volume":"62","author":"Johnson","year":"2021","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.yrtph.2026.106051_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105672","article-title":"Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine","volume":"152","author":"Jolly","year":"2024","journal-title":"Regul. Toxicol. Pharmacol.: RTP (Regul. Toxicol. Pharmacol.)"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106051_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.fct.2003.08.006","article-title":"Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet","volume":"42","author":"Kroes","year":"2004","journal-title":"Food Chem. Toxicol.: Int. J. Pub. British Indust. Biol. Res. Assoc."},{"key":"10.1016\/j.yrtph.2026.106051_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105640","article-title":"Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: development and application of the Carcinogenic Potency Categorization Approach (CPCA)","volume":"150","author":"Kruhlak","year":"2024","journal-title":"Regul. Toxicol. Pharmacol.: RTP (Regul. Toxicol. Pharmacol.)"},{"issue":"1\u20133","key":"10.1016\/j.yrtph.2026.106051_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2005.04.002","article-title":"Detailed review of transgenic rodent mutation assays","volume":"590","author":"Lambert","year":"2005","journal-title":"Mutat. Res."},{"issue":"11","key":"10.1016\/j.yrtph.2026.106051_bib29","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1007\/s00204-022-03347-6","article-title":"Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s","volume":"96","author":"Li","year":"2022","journal-title":"Arch. Toxicol."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106051_bib30","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1093\/carcin\/6.12.1679","article-title":"Induction of liver tumors in rats by nitrosodiethanolamine at low doses","volume":"6","author":"Lijinsky","year":"1985","journal-title":"Carcinogenesis"},{"issue":"8","key":"10.1016\/j.yrtph.2026.106051_bib31","first-page":"2089","article-title":"Dose-response study with N-nitrosomorpholine in drinking water of F-344 rats","volume":"48","author":"Lijinsky","year":"1988","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106051_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/mutage\/geae001","article-title":"N-Nitrosodimethylamine investigations in MutaTMMouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations","volume":"39","author":"Lynch","year":"2024","journal-title":"Mutagenesis"},{"key":"10.1016\/j.yrtph.2026.106051_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2023.108466","article-title":"Error-corrected next generation sequencing\u2014Promises and challenges for genotoxicity and cancer risk assessment","volume":"792","author":"Marchetti","year":"2023","journal-title":"Mutat. Res., Rev. Mutat. Res."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106051_bib34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10408444.2017.1423462","article-title":"Development of an adverse outcome pathway for chemically induced hepatocellular carcinoma: case study of AFB1, a human carcinogen with a mutagenic mode of action","volume":"48","author":"Moore","year":"2018","journal-title":"Crit. Rev. Toxicol."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106051_bib35","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.xphs.2023.01.027","article-title":"N-Nitrosamine formation in pharmaceutical solid drug products: experimental observations","volume":"112","author":"Moser","year":"2023","journal-title":"J. Pharmaceut. Sci."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106051_bib36","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The nitrosamine \u201cSaga\u201d: lessons learned from five years of scrutiny","volume":"27","author":"Nudelman","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.yrtph.2026.106051_bib37","series-title":"Test No. 488: Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106051_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/em.22599","article-title":"Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: a report from the 8th International workshop on Genotoxicity Testing (IWGT)","author":"Parsons","year":"2024","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.yrtph.2026.106051_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2024.114498","article-title":"Risk characterization of N-nitrosodimethylamine in pharmaceuticals","volume":"186","author":"Paustenbach","year":"2024","journal-title":"Food Chem. Toxicol.: Int. J. Pub. British Indust. Biol. Res. Assoc."},{"issue":"23 Pt 2","key":"10.1016\/j.yrtph.2026.106051_bib40","first-page":"6415","article-title":"Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: a detailed dose-response study","volume":"51","author":"Peto","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.yrtph.2026.106051_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105681","article-title":"N-nitrosamine impurity risk assessment in pharmaceuticals: utilizing in Vivo mutation relative potency comparison to establish an acceptable intake for NTTP","volume":"152","author":"Powley","year":"2024","journal-title":"Regul. Toxicol. Pharmacol.: RTP (Regul. Toxicol. Pharmacol.)"},{"issue":"23","key":"10.1016\/j.yrtph.2026.106051_bib42","first-page":"6912","article-title":"Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and areca-derived N-nitrosamines","volume":"48","author":"Rivenson","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.yrtph.2026.106051_bib43","article-title":"Appropriate in vivo follow-up assays to an in vitro bacterial reverse mutation (Ames) test positive investigational drug candidate (active pharmaceutical ingredient), drug-related metabolite, or drug-related impurity","volume":"868\u2013869","author":"Robison","year":"2021","journal-title":"Mutat. Res., Genet. Toxicol. Environ. Mutagen."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106051_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/em.70012","article-title":"Using N-Nitrosodiethanolamine (NDELA) and N-Nitrosopiperidine (NPIP) transgenic rodent gene mutation data and quantum mechanical modeling to derive potency-based acceptable intakes for NDSRIs lacking robust carcinogenicity data","volume":"66","author":"Roper","year":"2025","journal-title":"Environ. Mol. Mutagen."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106051_bib45","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","article-title":"The landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Schlingemann","year":"2023","journal-title":"J. Pharmaceut. Sci."},{"issue":"6","key":"10.1016\/j.yrtph.2026.106051_bib46","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00204-024-03731-4","article-title":"Evaluating the mutagenicity of N-nitrosodimethylamine in 2D and 3D HepaRG cell cultures using error-corrected next generation sequencing","volume":"98","author":"Seo","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106051_bib47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.yrtph.2019.01.007","article-title":"Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products","volume":"103","author":"Snodin","year":"2019","journal-title":"Regul. Toxicol. Pharmacol.: RTP (Regul. Toxicol. Pharmacol.)"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106051_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1021\/acs.chemrestox.3c00327","article-title":"Mechanisms of nitrosamine mutagenicity and their relationship to rodent carcinogenic potency","volume":"37","author":"Snodin","year":"2024","journal-title":"Chem. Res. Toxicol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106051_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/mutage\/gev043","article-title":"Estimating the carcinogenic potency of chemicals from the in vivo micronucleus test","volume":"31","author":"Soeteman-Hern\u00e1ndez","year":"2016","journal-title":"Mutagenesis"},{"key":"10.1016\/j.yrtph.2026.106051_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105460","article-title":"A deep dive into historical Ames study data for N-nitrosamine compounds","volume":"143","author":"Tennant","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106051_bib51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/mutage\/gead033","article-title":"Ames test study designs for nitrosamine mutagenicity testing: qualitative and quantitative analysis of key assay parameters","volume":"39","author":"Thomas","year":"2024","journal-title":"Mutagenesis"},{"key":"10.1016\/j.yrtph.2026.106051_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104749","article-title":"Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data","volume":"116","author":"Thresher","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106051_bib54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/em.70006","article-title":"Benchmark response (BMR) values for In Vivo mutagenicity endpoints","volume":"66","author":"White","year":"2025","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.yrtph.2026.106051_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/em.70007","article-title":"Re-Evaluating acceptable intake: a comparative Study of N-Nitrosomorpholine and N-Nitroso reboxetine potency","author":"Zhang","year":"2025","journal-title":"Environ. Mol. Mutagen."},{"issue":"6\u20137","key":"10.1016\/j.yrtph.2026.106051_bib56","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/em.22615","article-title":"Assessing the genotoxicity of N-nitrosodiethylamine with three in vivo endpoints in male Big blue\u00ae transgenic and wild-type C57BL\/6N mice","volume":"65","author":"Zhang","year":"2024","journal-title":"Environ. Mol. Mutagen."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T19:26:19Z","timestamp":1772565979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"alternative-id":["S0273230026000243"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106051","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106051"}}